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Abstract: Clinical audit of invasive mold disease (IMD) in hematology patients is inefficient due to
the difficulties of case finding. This results in antifungal stewardship (AFS) programs preferentially
reporting drug cost and consumption rather than measures that actually reflect quality of care.
We used machine learning-based natural language processing (NLP) to non-selectively screen
chest tomography (CT) reports for pulmonary IMD, verified by clinical review against international
definitions and benchmarked against key AFS measures. NLP screened 3014 reports from 1 September
2008 to 31 December 2017, generating 784 positives that after review, identified 205 IMD episodes
(44% probable-proven) in 185 patients from 50,303 admissions. Breakthrough-probable/proven-IMD
on antifungal prophylaxis accounted for 60% of episodes with serum monitoring of voriconazole
or posaconazole in the 2 weeks prior performed in only 53% and 69% of episodes, respectively.
Fiberoptic bronchoscopy within 2 days of CT scan occurred in only 54% of episodes. The average
turnaround of send-away bronchoalveolar galactomannan of 12 days (range 7–22) was associated
with high empiric liposomal amphotericin consumption. A random audit of 10% negative reports
revealed two clinically significant misses (0.9%, 2/223). This is the first successful use of applied
machine learning for institutional IMD surveillance across an entire hematology population describing
process and outcome measures relevant to AFS. Compared to current methods of clinical audit,
semi-automated surveillance using NLP is more efficient and inclusive by avoiding restrictions based
on any underlying hematologic condition, and has the added advantage of being potentially scalable.
Keywords: invasive fungal diseases; antifungal stewardship; machine learning; natural language
processing; aspergillosis; mold infections
1. Introduction
Antifungal stewardship (AFS) is a growing area of clinical importance in hospitals worldwide
that manage patients vulnerable to invasive fungal diseases (IFD) [1,2]. Like antibiotics, overuse of
antifungal drugs is common but largely driven by the high morbidity and mortality of IFD [3] combined
with insensitive diagnostic tools [4,5]. A recent systematic review showed that the effectiveness of
most AFS programs is measured by savings in antifungal drug cost and consumption [6], a secondary
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consideration of AFS [7], rather than by indicators that actually reflect good quality of care such
clinical outcomes, effectiveness of antifungal prophylaxis and processes including therapeutic drug
monitoring, and speed of the diagnostic work-up [1,6,7]. Most AFS interventions preferentially target
high-risk patients such as hemopoietic stem cell transplant (HSCT) recipients and acute leukemia
patients as well as Candida infections which are easier to monitor than the more common [3,8,9] but
diagnostically challenging invasive mold diseases (IMD) like Aspergillosis [6].
Surveillance, audit and feedback are fundamental to antimicrobial stewardship and facilitate the
implementation, assessment and benchmarking of these programs. Whilst such mechanisms are well
established for antibiotics [10], they do not exist for AFS. Recent British guidelines cite surveillance and
audit as the first step in AFS in order to identify gaps in practice [1]. Similar views from low income
settings like India recognize that regular audit and feedback of local (i.e., institutional) epidemiology
acquired through continuous surveillance best drive “corrective and preventive actions” in AFS
practice [2].
Surveillance and audit of IMD, is inefficient and laborious whether undertaken
retrospectively [8,9,11–15] or less often, prospectively [3,16,17]. The largest prospective fungal
surveillance study by the TRANSNET consortium (2001–2006) was characterized by high operational
costs, targeted only HSCT recipients rather than all hematology patients, and had a finite timeline with
the high cost of case finding and data collection posing a major barrier [3]. Retrospective studies have
usually been restricted to specific risk groups [8,9,11,12] or individual antifungal agents [9,13,14] due
to an inability to perform population scale surveillance efficiently.
In response to the difficulties of IMD surveillance we developed natural language processing
(NLP) of chest computed tomography (CT) reports [18–20] to facilitate surveillance of IMD. Chest CT
was targeted for screening because it is the cornerstone of IMD diagnosis: IMD usually presents as
culture-negative pneumonia in 90–100% of cases [3,16,17]; CT is the first investigation performed when
IMD is suspected; it is widely available and performed with a higher frequency than invasive tests like
fiberoptic bronchoscopy. Although the radiographic features of IMD are non-specific, they are highly
persuasive in the appropriate clinical context [21] even when results of microbiological investigations
are negative [22]. It should be emphasized that NLP is not a diagnostic tool, but rather a computational
method of analyzing radiologist language for features of fungal pneumonia that is useful for disease
classification [18–20].
The NLP model used here [18,19] is part of a platform technology called fungalAiTM (www.
fungalAi.com) that also includes deep learning-based image recognition for fungal pneumonia on chest
CT in development [23] and an expert system that integrates antifungal drug and microbiology data [24]
to improve fungal prediction. Technical descriptions of the development and internal validation of the
statistical NLP model used here [18,19] have been published. The aim of this study was to characterize
institutional IMD burden along with process and outcome measures relevant to AFS in order to identify
areas for improvement. What follows is a clinical (rather than technical) study of applied machine
learning that represents an in silico analysis of NLP for IMD surveillance and audit, describing a range
of AFS measures reflecting quality of care for an entire hematology population.
2. Methods
2.1. Study Design and Setting
The Alfred Hospital is a 638-bed quaternary, university-affiliated, center with trauma, heart/lung
transplantation, allogeneic hematopoietic stem cell transplantation (HSCT), cystic fibrosis, burns,
hyperbaric medicine and human immunodeficiency virus state-wide services. This was a retrospective
observational cohort study from 1 September 2008 to 31 December 2017 coinciding with implementation
of our data warehouse which contains imaging and clinical data. Ethics approval was obtained from
Alfred Health Office of Ethics (Project no. 104/17) with a waiver of consent granted.
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At our center chest CT is performed when IMD is suspected with subsequent bronchoalveolar
lavage (BAL) or biopsy performed as tolerated. A diagnostic driven approach using serum
galactomannan or aspergillus PCR surveillance is not routine, and when performed these are send-away
tests. Empiric antifungal therapy is sometimes commenced in the presence of suspicious radiologic
changes while diagnostic investigations continue. All patients have been treated in high efficiency
particulate air-filtration rooms since April 2005. Antifungal prophylaxis is prescribed according
to institutional protocols noting that intermittent liposomal amphotericin (LAMB) prophylaxis is
administered to patients unable to take azole drugs, such as patients on experimental medication
enrolled in clinical trials.
An infectious diseases physician and registrar perform regular ward rounds on a referral basis for
patients admitted under the hematology service. There is no formal AFS program and the infectious
diseases service works in collaboration with hematology and pharmacy services.
2.2. Clinical Definitions
IMD was classified by investigators (MAR, DB) according to international definitions [22], with
possible infections upgraded to probable or proven categories if a positive microbiological indicator
such as isolation of a fungal pathogen or positive galactomannan in bronchoalveolar lavage (BAL)
was present [22]. Possible cases lacked positive microbiology but satisfied radiologic and host
criteria [22]. In addition, possible cases had documentation in the medical record at the time of
diagnosis and/or follow-up (where patients were not palliated), of fungal infection being suspected.
If supportive documentation was not found, possible cases were excluded. Our inclusion of possible
cases reflects their predominance in real-world practice [15,16] and is consistent with recent AFS
guidelines supporting their inclusion [1].
Date of IFD diagnosis was the first day of suspicious radiologic abnormality for patients with
possible infection, or positive microbiologic test for patients with probable or proven infection,
consistent with previous work [8]. Prolonged neutropenia was defined as absolute neutrophil count
<0.5 × 109/L for ≥10 days within 30 days of IMD diagnosis.
Breakthrough-IMD was defined as probable/proven IMD occurring during the course of antifungal
prophylaxis or in the 14 days after cessation of antifungal prophylaxis in patients who received at
least 7 days of therapy to approximate steady state, reflecting recent expert opinion [25] and other
studies [8,14]. Targets for therapeutic drug monitoring (TDM) for antifungal prophylaxis came from
our institutional guidelines. Given that treatment of invasive aspergillosis can be over 50 weeks [26],
IMD episodes with the same causative fungus in a 12-month period were considered duplicates
and excluded, as were episodes with non-filamentous fungi (e.g., Candida and Pneumocystis) unless
co-infection with IMD was present.
Diagnostic delay and its impact on empiric antifungal consumption was determined for a subgroup
of probable IMD episodes diagnosed by galactomannan on bronchoalveolar lavage only. Antifungal
consumption measured in defined daily dosages (DDD) was evaluated for two intervals, being time to
fiberoptic bronchoscopy from diagnostic chest CT scan (interval 1), and the time from bronchoscopy to
a galactomannan result reflecting the turnaround time of this send-away test, in interval 2.
2.3. Summary of NLP Model Development
NLP is a machine learning based text classifier that aims to improve surveillance of IMD by
screening unstructured chest CT reports for the possibility of fungal pneumonia [18–20]. NLP generates
a probabilistic output ranging from 0%–100% [18–20], assigning a binary classification (1 = possible
fungal for further review, 0 = not fungal, else) at a threshold of ≥50%. A positive classification triggers
review of the medical record to confirm or reject IMD according to international definitions [22].
Development of NLP based on a statistical model was a strenuous task [18,19] involving the manual
extraction of 1880 free-text CT reports from 270 patients with IMD and 257 control patients from 3
major Victorian hospitals manually identified from completed mycology studies, clinical databases,
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pharmacy and microbiology records [18,19]. A subgroup of 449 reports were hand labeled for features
of IMD using pre-specified guidelines, at sentence, report, and patient levels [18,19]. The entire report
was used for training including reason for the scan, main text, and conclusion. A variety of machine
learning, rule-based, and hybrid systems were tested with feature types including bag of words, bag of
phrases, and bag of concepts, as well as report-level structured features [18,19]. The best system using
support vector machines, achieved a sensitivity over unseen data at a report level of 91%, specificity
of 79%, receiver operating characteristic area of 0.92, and with few clinically significant missed cases
(0.9%), demonstrating its value as a screening tool for IMD [18]. At the patient level, performance was
outstanding, with NLP identifying 100% of IMD patients (n = 188) from a dataset 1247 reports [19]
suggesting that if NLP failed to flag the first suggestive CT scan, it would eventually capture the
patient on subsequent scans as the radiologist’s language became more conclusive. The statistical
model we originally developed [18,19] was changed to a cascaded latent variable model that combined
logistic regression and expectation maximization [27] used in this study, that outperformed the earlier
models [18,19] and has since progressed to a deep learning-based NLP model that is easier to train [20].
2.4. Clinical Data and Audit Methodology
We obtained CT reports from our radiology department from 1 September 2008 to 31 December
2017 belonging to hematology patients. These included any acquisition protocol including the chest
such as high-resolution CT, low dose CT, CT pulmonary angiography, and chest CT in combination
with any other anatomic site (e.g., brain, neck, abdomen, or pelvis) irrespective of the clinical indication.
Reports were screened by NLP [18,19], with positive reports undergoing further review. To determine
the rate of false negatives or cases missed by NLP, we (MAR, DB) randomly audited the medical
records associated with a convenience sample of 10% negative reports associated with a probability of
<50%.
Variables collected included demographics, underlying hematologic disease, HSCT details,
histologically proven graft vs. host disease (GVHD), neutropenia, hospitalization duration, exposure
to T-cell immunosuppressants, microbiology, histopathology, receipt of antifungal prophylaxis, TDM,
invasive diagnostic tests, antifungal drug prescribing, intensive care unit (ICU) admission, and all-cause
mortality at 6 or 12 weeks. Annual admissions to the hematology unit were obtained from administrative
data but included only multi-day hospitalizations lasting >1 day to determine disease incidence. Data
were recorded on a REDcaps database.
2.5. Statistical Analysis
Descriptive analyses were based on percentages and frequencies for categorical variables and
for continuous variables, means and standard deviations, or medians and interquartile ranges if the
data were skewed. Yearly incidence was calculated as the number of IMD cases per 1000 occupied
bed-days. A chi-square statistic for trend was used to assess changes in IMD incidence over the study
period. A p value less than 0.05 was considered statistically significant. Analyses were done using
Stata 15 (Stata Corp, College Station TX, USA).
3. Results
3.1. An Overview of IMD Epidemiology
NLP screened 3014 CT reports flagging 784 reports as possibly fungal for subsequent medical
record review (Figure 1). A sample of 10 anonymized reports with NLP probabilities and binary
outputs is shown in Supplementary Table S1. Following medical record review and adjudication
using international criteria [22], we identified 205 IMD episodes across 50,303 admissions. Among the
185 patients with IMD, 68% were male with median age 58 years (IQR 44-67); 30% were elderly (i.e.,
65 years or more) and 49% of episodes were associated with active hematological disease (Table 1).
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Table 1. Characteristics of patients with invasive mold disease.
Characteristics N (%)
Number of patients 185
Age, years
Median [IQR] 58 (44–67)
Elderly (≥65 years) 56 (30)
Male gender 125 (68)
Number of IMD episodes 205
Outpatients 14 (6.8)
Length of hospitalization, days
Median [IQR] 29 (15–43)
Underlying hematologic disease, n = 138 non-HSCT episodes
Acute myeloid leukemia 93 (67)
Acute lymphoblastic leukemia 17 (12)
Non-Hodgkin lymphoma 10 (7.3)
Myelodysplastic syndrome 5 (3.6)
Multiple myeloma 3 (2.2)
Chronic lymphocytic leukemia 3 (2.2)
Hodgkin lymphoma 2 (1.5)
Acute promyelocytic leukemia 1 (0.8)
Other a 4 (2.9)
HSCT recipients 67 (33)
Type of HSCT
Autologous 15 (22)
Allogeneic 52 (78)
Matched related 35 (52)
Unrelated 16 (24)
Mismatched 1 (1.5)
Early post allo-HSCT (≤100 days) 18 (35%)
Late post allo-HSCT (>100 days) 34 (65%)
Stem cell source in allogeneic-HSCT recipients, n = 52 episodes
Peripheral blood 48 (94)
Cord blood 2 (3.9)
Marrow 1 (2.0)
Status of hematological disease, n = 203 episodes b
Newly diagnosed or receiving first induction therapy 49 (24)
Complete remission 55 (27)
Active hematologic disease (partial remission, progression, relapsed/refractory) 99 (49)
Enrolled in clinical trial 42 (20)
Neutropenia ≤0.5 × 109/L lasting ≥10 days in 30 days prior to IMD diagnosis 108 (53)
Duration of neutropenia ≤0.5 × 109/L, median [IQR] 22 (15–37)
a Includes 1 patient with acute leukemia of ambiguous lineage, two mixed phenotype acute leukemia, 1 each of
blastic dendritic cell neoplasm and blastic plasmacytoid dendritic cell neoplasm. b Non-malignant conditions
(n = 2) excluded. Abbreviations: IMD, invasive mold disease; IQR, interquartile range; HSCT, hemopoietic stem
cell transplant.
Among non-HSCT episodes, we noted a predilection for patients with acute myeloid leukemia
(AML, 67%), acute lymphoblastic leukemia (ALL, 12%) and non-Hodgkin’s lymphoma (NHL, 7.3%).
Enrolment in a clinical trial was present in 20% of IMD episodes, with AML the primary condition
in 83%. Among the 33% of HSCT recipients, 78% were allogeneic with 35% (18/52) occurring early
(i.e., ≤100 days) post-transplant. Periods of risk represented by median onset of IMD from diagnosis
of hematological disease varied by hematological condition and was substantially later in onset for
patients with multiple myeloma and chronic lymphocytic leukemia (Supplementary Figure S1). Yearly
incidence of IMD decreased over the study period from 2.85 per 1000 occupied bed-days in 2009 to
1.60 in 2017 (test for trend, p = 0.006, Supplementary Figure S2).
IMD episodes were possible and probable/proven in 56% and 44%, respectively (Table 2).
Aspergillus species accounted for the majority (73%) of probable/proven episodes followed by the
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Mucorales at 18% with non-Aspergillus molds accounting for 31% of episodes. The number of
non-Aspergillus molds ranged from 1 to 8 per year (mode = 3), with incidence remaining fairly steady
over the 9-year study period (test for trend, p = 0.057).
Table 2. Characteristics of IMD episodes.
IMD Characteristics, n = 205 Episodes N (%)
EORTC/MSG classification
Proven/probable 90 (44)
Possible 115 (56)
Site of infection
Localized 190 (93)
Disseminated 15 (7.3)
Site of involvement
Lung only 198 (97)
Sinus 5 (2.4)
Bloodstream 4 (2.0)
Liver 2 (1.0)
Spleen 2 (1.0)
CNS 2 (1.0)
Other a 4 (2.0)
Organism in probable/proven IMD episodes, n = 90 episodes b
Aspergillus species 66 (73)
Aspergillus fumigatus 20 (30)
Non-fumigatus Aspergillus species 9 (14)
Aspergillus species not otherwise specified 25 (38)
Positive galactomannan from BAL 24 (27)
Non-aspergillus molds 31 (34)
Mucorales 16 (18)
Lomentospora prolificans 5 (5.6)
Other rare molds c 10 (11)
Mixed fungal infections 8 (8.9)
Aspergillus PCR positive d 13 (14)
Panfungal PCR positive d 5 (5.6)
Possible IMD episodes 115
Aspergillus PCR positive 12 (10)
Panfungal PCR positive 5 (4.3)
Clinical outcomes
ICU admission 53 (26)
Invasive ventilation 17 (32)
All-cause mortality, n = 130 evaluable episodes
6 week 52 (40)
12 week 68 (52)
a Other refers to colon (n = 1), heart and great vessels (n = 1), larynx (n = 1), pancreas and kidneys (n = 1). b More
than one species in some episodes. c Paecilomyces spp. (n = 2), Phialemonium spp. (n = 1), Penicillium spp. (n = 1),
Fusarium spp. = 2, Acremonium spp. (n = 2), Alternaria alternata (n = 1), Saccharomyces (n = 1). d Aspergillus PCR was
positive on bronchoalveolar lavage specimens; Panfungal PCR was positive on 3 tissue specimens (1 sinus, 2 lung)
and 2 bronchoalveolar lavage specimens. Abbreviations: IMD, invasive mold disease; EORTC/MSG, European
Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National
Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG 22; PCR, polymerase chain reaction;
ICU, intensive care unit; IQR, interquartile range.
Random audit of 10% of reports (n = 223) screened negative by NLP, revealed 2 patients with
possible IMD who should have been flagged positive but were missed for unclear reasons, resulting in
an overall miss rate of 0.9% (2/223) (Supplementary Figure S3). There were 2 cases (2009, 2011) from
the training dataset from Alfred Health (2003–2011) used to develop the NLP model that also appeared
in this study.
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3.2. Process and Outcome Measures: Breakthrough-IMD, TDM, Missed Prophylaxis Opportunities
Breakthrough probable/proven IMD on antifungal prophylaxis occurred in 60% of probable/proven
cases (n = 53/88) (Table 3).
Table 3. Gaps and opportunities for antifungal stewardship.
Characteristics N (%)
Breakthrough probable/proven IMD a 53/88 (60)
Posaconazole 15 (28)
Liposomal amphotericin B 17 (32)
Voriconazole 13 (25)
Fluconazole 6 (11)
Caspofungin 2 (3.8)
TDM performed in 2 weeks prior to breakthrough probable/proven IMD diagnosis b
Posaconazole prophylaxis 8/15 (53)
Therapeutic 5 (63)
Voriconazole prophylaxis 9/13 (69)
Therapeutic 7 (78)
Invasive diagnostic tests, (n = 205 episodes) 170 (83)
Fiberoptic bronchoscopy 123 (60)
Lung 27 (13)
Sinus 8 (3.9)
Other site 9 (4.3)
Lung resection 3 (1.4)
Interval from CT to fiberoptic bronchoscopy, n = 117 episodes c
Median time [IQR], days 2 (1–5)
≤2 days 63 (54)
3–5 days 38 (32)
>5 days 16 (14)
Time from bronchoalveolar lavage galactomannan request to result, n = 24 episodes, mean
(range), days 12 (7–22)
Potential missed opportunities for antifungal prophylaxis in probable/proven IMD episodes d
Early post allogeneic-HSCT (≤100 days) 3/18 (17)
Chronic GVHD e in 60 days prior to IMD diagnosis 6/13 (46)
Neutrophils ≤0.5 × 109/L for >3 weeks and <5 weeks 9/27 (33)
Neutrophils ≤0.5 × 109/L for >5 weeks 9/28 (32)
a Breakthrough IMD defined as onset during antifungal prophylaxis and up to 14 days after cessation in patients
who received at least 7 days of consecutive antifungal therapy. b Trough levels were considered therapeutic if
>0.7 mg/L and >1.0 mg/L for posaconazole and voriconazole respectively according to institutional guidelines.
c Defined as the time from computed tomography (CT) scan to fiberoptic bronchoscopy, with diagnostic CT scan
assumed to be immediately prior to fiberoptic bronchoscopy. Bronchoscopy not prompted by an abnormal CT scan
excluded (n = 6 episodes). d High to intermediate risk factors for IMD in guidelines [28]. e Histologically proven
GVHD. Abbreviations: IMD, invasive mold disease; TDM, therapeutic drug monitoring; IQR, interquartile range;
HSCT, hemopoietic stem cell transplant; GVHD, graft vs. host disease.
The majority (89%) of breakthrough-IMD was associated with mold-active prophylaxis including
posaconazole (n = 15, 28%), intermittent LAMB prophylaxis (n = 17, 32%), voriconazole (n = 13, 25%),
and caspofungin (n = 2, 3.8%), while 11% (n = 6) complicated fluconazole prophylaxis (Figure 2).
Breakthrough-probable/proven IMD episodes complicating intermittent LAMB prophylaxis included 6
ALL patients receiving induction chemotherapy, and a further 8 AML patients where 5 were enrolled
in clinical trials that contraindicated azole use.
For those breakthrough-probable/proven IMD cases receiving posaconazole or voriconazole
prophylaxis, TDM was performed in the 14 days prior to IMD diagnosis in (53%) 8/15 of posaconazole
and 9/13 (69%) of voriconazole recipients and was therapeutic according to our institutional guidelines
in 63% and 78% of recipients, respectively.
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3.3. Effect of Diagnostic Delays on Antifungal Consumption
An invasive diagnostic test was performed in 83% (170, 170/205) of episodes, with fiberoptic
bronchoscopy the most common procedure (60%, 123/205) (Table 3) that increased over the study period
(Supplementary Figure S4). The median time from CT scan to fiberoptic bronchoscopy was 2 days but
was variable with 54% occurring within 2 days, 32% occurring between 3 to 5 days and 14% occurring
5 days or more (Table 3). The average time of galactomannan test turnaround was 12 days (range 7–22
days) for 24 IMD episodes associated with a positive bronchoalveolar lavag galactomannan.
A subgroup analysis f 19 probabl IMD episodes diagnosed solely by a positive bronchoalveolar
galactomannan r ve led a high median emp ric antifungal con umption in in erval 2 asso iated with
the long turnaround time of the galactomannan result, dominated by voriconazole at 14 DDDs and
followed by LAMB at 10.5 DDDs per episode, as shown in Supplementary Figure S5.
3.4. Probable/Proven IMD in Patients Who Did Not Receive Prophylaxis
variety of patients developed probable/proven IMD (n = 35 episodes) who did not receive
antifungal prophylaxis in the 14 days prior to IMD diagnosis (Supplementary Figure S6). Non-transplant
groups ha either newly diagnosed or refractory disease. Among allogeneic-HSCT recipients, three
probable/proven IMD episodes occurred early post-transplant (i.e., at 33, 40, 64 days), and 6 episodes
complicated histologically proven chronic GVHD that was present in the 60 days prior to IMD diagnosis,
representing potential missed prophylaxis opportunities (Table 3).
3.5. Clinical Outcomes
Resource utilization was high (Table 2) with ICU admissi n required in 26% of epis d s, of whom
32% r quired invasive ventilatio . Of 130 evaluable episo es, 6 and 12 week all-cause mortality was
40% and 52%, re pectively.
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4. Discussion
We report the first successful use of applied machine learning for institutional case-finding and
audit of IMD in an entire hematology population. This approach provided detailed patient-level
data which is fundamental to AFS but rarely achieved in practice [6]. We were able to characterize
our highest risk as well as low risk/emerging patient groups, breakthrough infections on a range of
prophylactic antifungal drugs and missed prophylaxis opportunities. Our semi-automated approach
to surveillance and audit still required manual chart review but made the finding of a rare infection
feasible. This is significant considering we identified on average 22 incident IMD episodes from over
5000 admissions annually to the hematology unit, which would not have been possible without this
technology. We were also able to establish a baseline for outbreak detection, describe reproducible
metrics like the impact of diagnostic delays on empiric antifungal consumption and apply figures to
benchmark recommendations for optimum patient care in AFS [7] beyond the commonly reported
antifungal consumption and cost [6]. This targeted review of process and outcome measures for
each IMD episode provided a rich overview of our fungal epidemiology and AFS practice, laying the
groundwork for future quality improvement work.
Missed opportunities and variability from institutional guidelines underscore the importance of
regular clinical audit. There were three patients in the early (within 100 days) post allogeneic-HSCT
period who qualified for prophylaxis but did not receive it in the previous 14 days, in addition to 6 HSCT
recipients with concurrent histologically-proven GVHD where prophylaxis may have been indicated.
Of concern, 60% of the 88 evaluable episodes with probable/proven IMD represented breakthrough-IMD
on antifungal prophylaxis when applying a definition concordant with recent expert opinion [25].
Breakthrough-IMD also occurred in a variety of conditions where a standardized approach is lacking [29].
For example, 32% (n = 17/53 episodes) of probable/proven breakthrough-IMD complicated intermittent
LAMB prophylaxis. These included 6 episodes during induction chemotherapy for ALL, where
interactions between azole drugs and vinca alkaloids are well recognized [30], and a further 5 episodes
in AML patients on experimental drugs contraindicating azole use. Although posaconazole TDM is
contentious [31], it is advocated in our setting, but like voriconazole TDM, was performed inconsistently
in the 14 days prior to breakthrough probable/proven IMD in those patients receiving prophylaxis.
An increase in the performance of fiberoptic bronchoscopy over the study period is encouraging
but room for improvement remains, especially given our high incidence of non-Aspergillus molds which
comprised 31% of probable/proven episodes. Only 54% of fiberoptic bronchoscopies were performed
within 2 days of CT scan, which is suboptimal considering that the diagnostic yield declines after 4
days from symptom (not radiological) onset [5]. We identified potential cost savings by quantifying
the impact of diagnostic delays on empiric antifungal consumption during (1) time from CT scan to
bronchoscopy and (2) galactomannan test turnaround, in a subgroup of 19 probable IMD episodes
where bronchoalveolar lavage galactomannan established the diagnosis. The mean turnaround time
for a send-away galactomannan result of 12 days was associated with high liposomal amphotericin
consumption which has clear implications on cost, especially as a negative galactomannan usually
results in streamlining or cessation of empiric antifungal drugs in our setting. This data represents a
baseline from which improvements in bronchoscopy timeliness and on-site rapid diagnostics can be
argued, but building a business case will rely on AFS teams presenting locally relevant data as we
have done.
Our study has several limitations, including its retrospective nature and single center focus. While
our findings may not be extrapolated to other centers, the methodology of NLP assisted surveillance
and audit is generalizable. The in silico validation of our NLP model described here is the step prior to
real-world validation and implementation of applied artificial intelligence [32]. We are progressing
through those stages with real-world multi-center prospective validation of our deep learning-based
NLP model underway (ClinicalTrials.gov NCT03793231). The combination of microbiology and
antifungal drug data with NLP predictions in our expert system [24] does decrease false positives, but
is challenging to implement due to the cost of integrating legacy systems in hospitals. NLP is tuned for
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fungal pneumonia, and may miss extrapulmonary presentations like fungaemia or sinusitis. Finally,
NLP was associated with a low miss rate of 0.9% but the reason for this failure is unclear, pointing to
the “black-box”-like inscrutability of artificial intelligence [32].
5. Conclusions
Surveillance and audit of IMD is fundamental to AFS programs [1,6,7] but is currently inefficient
and restrictive. Valerio et al. recommends that AFS programs should have measurable indicators
that are prospectively recorded and simple to obtain, allowing AFS teams to focus on intervention
rather than data collection [33]. We would add that these indicators should be patient-level and reflect
quality of care, rather than fluctuations in drug consumption or cost. NLP is a valuable tool in the AFS
armamentarium that represents a potentially scalable solution to the challenge of surveillance and
audit, that leverages unstructured radiology data which is a readily available resource in hospitals.
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made with positive bronchoalveolar lavage galactomannan only, n = 19 episodes, Figure S6: Probable/proven IMD
episodes (total n = 35) where antifungal prophylaxis was not administered in the 14 days prior to IMD diagnosis.
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